Phase 2 study of bevacizumab beyond progression disease for glioblastoma treated with key therapeutics.

Trial Profile

Phase 2 study of bevacizumab beyond progression disease for glioblastoma treated with key therapeutics.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms BIOMARK
  • Sponsors EPS Corporation
  • Most Recent Events

    • 16 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Apr 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network record.
    • 03 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top